![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY)
|
|
|
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
J van Wyk,1 F Ajana,2 F Bisshop,3 S De Wit,4 O Osiyemi,5 J Portilla,6 J-P Routy,7 C Wyen,8
M Ait-Khaled,1 M-C Nascimento,1 KA Pappa,9 R Wang,9 J Wright,10 B Wynne,9 M Aboud,1 KY Smith9
1ViiV Healthcare, Brentford, UK; 2Centre Hospitalier de Tourcoing, Tourcoing, France; 3Holdsworth House Medical Brisbane, Queensland, Australia; 4CHU St-Pierre, Brussels, Belgium; 5Triple O Research Institute PA, West Palm Beach, FL, USA; 6Hospital General Universitario de Alicante, Alicante Spain; 7McGill University Health Center, Montreal, QC, Canada; 8Praxis am Ebertplatz, Cologne, Germany;
9ViiV Healthcare, Research Triangle Park, NC, USA; 10GlaxoSmithKline, Stockley Park, UK
![1016201](../images/101620/101620-1/1016201.gif)
![1016202](../images/101620/101620-1/1016202.gif)
![1016203](../images/101620/101620-1/1016203.gif)
![1016204](../images/101620/101620-1/1016204.gif)
![1016205](../images/101620/101620-1/1016205.gif)
![1016206](../images/101620/101620-1/1016206.gif)
![1016207](../images/101620/101620-1/1016207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|